Combating Antibiotic Resistance Through the Health Impact Fund

Author granted license

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

Document Type

Book Chapter

Publication Date

3-2013

Editor(s)

I. Glenn Cohen

ISBN

9780199332878

Publisher

Oxford University Press

Language

en-US

Abstract

This chapter illustrates how antibiotic resistance distorts markets for innovative antibiotics in unusual and counterintuitive ways. It also clarifies how proposals to produce a Health Impact Fund (HIF) that rewards companies for the health impacts of their drugs can be used to coordinate effectively global use of antibiotics in a way that manages the threat of resistance. The HIF would foster the development of new high-impact medicines. It would also raise appropriate financial access to new medicines. On the other hand, the antibiotic HIF (aHIF) is very appealing as a global coordination mechanism for antibiotic R&D. It is also scalable throughout the world, despite weak health governance in many countries. It can be stated that the aHIF can serve a key role as a global coordination mechanism for antibiotics, ensuring that this important drug class does not fade away, but continues to serve humanity.

This document is currently not available here.

Find on SSRN

Please note the file available on SSRN may not be the final published version of this work.

Link to Publisher Site (BU Community Subscription)

Share

COinS